Ljiljana Stamatović

Delays in diagnosis and treatment of breast cancer: a multinational analysis

Jacek Jassem, Vahit Özmen, Florin Bacanu et al. · European Journal of Public Health · 2013 · 148 citations · Full text

Medicine, Oncology, Breast Oncology +12

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

Charles E. Geyer, M. Untch, Chiun‐Sheng Huang et al. · New England Journal of Medicine · 2025 · 115 citations · Full text

Medicine, Oncology, Pharmacology +14

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

Joyce O’Shaughnessy, Susana Sousa, Josefina Cruz et al. · European Journal of Cancer · 2021 · 74 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer

PierFranco Conte, Andreas Schneeweiß, Sibylle Loibl et al. · Cancer · 2020 · 30 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Factors influencing time to seeking medical advice and onset of treatment in women who are diagnosed with breast cancer in Serbia

Ljiljana Stamatović, S. Vasović, J. Trifunovic et al. · Psycho-Oncology · 2017 · 12 citations

Medicine, Oncology, Breast Oncology +7